ArticleAnnals of the rheumatic diseases2024

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry.

Blanca Hernández-Cruz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.